News

Lysogene, a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, announced that it has exercised its option to enter into an exclusive worldwide…
Read More...

Achilles Therapeutics plc a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, announced clinical manufacturing expansion in the…
Read More...

Direct Biologics, an innovative biotechnology company with a groundbreaking extracellular vesicle (EV) platform drug technology, announced that the U.S. Food and Drug Administration…
Read More...

Persephone Biosciences Inc., a synthetic biology company reimagining patient and infant health, and Ginkgo Bioworks, the leading horizontal platform for cell programming, today…
Read More...

Engitix Ltd (‘Engitix’), a biotechnology company developing a portfolio of programmes in fibrosis and solid tumours using its proprietary human extracellular matrix (ECM) platform,…
Read More...

SciRhom GmbH announced that it has nominated the anti-iRhom2 antibody it will advance into clinical development. For this antibody, the company has closed an agreement with a top-tier…
Read More...

Revive Therapeutics Ltd., a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide an update…
Read More...

Telix announces a licence agreement for Lilly’s olaratumab antibody, for diagnosis and treatment of human cancers. Telix is pleased to announce that it has entered into a licence…
Read More...

Kyttaro announces that it has entered into an agreement for the worldwide exclusive license of an anti-angiopoietin-like (ANGPTL) 3/8 monoclonal antibody program developed by Eli Lilly…
Read More...

Glenmark Pharmaceuticals Limited, an innovation-driven, global pharmaceutical company, announced that its subsidiary Glenmark Specialty S.A. (Glenmark) received approval from the Indian…
Read More...

Opus Genetics, a patient-focused gene therapy company developing treatments for inherited retinal diseases, announced a strategic manufacturing services agreement with National…
Read More...

BIOASIS TECHNOLOGIES INC. a biopharmaceutical company developing its proprietary xB3TM platform technology for the delivery of therapeutics across the blood-brain barrier (the “BBB”),…
Read More...

Ardelyx, Inc. a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs,…
Read More...

Moderna, Inc. a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced the first participants have been dosed in the Phase 1/2 study of the Company's…
Read More...

Harbour BioMed announced a global out-license agreement with AstraZeneca for CLDN18.2xCD3 bispecific antibody (HBM7022), a novel bispecific antibody generated from HBM's HCAb Based…
Read More...

Jazz Pharmaceuticals plc and Werewolf Therapeutics, Inc. announced that the companies have entered into a licensing agreement under which Jazz has acquired exclusive global development…
Read More...

Novavax, Inc. a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and Serum Institute of India Pvt. Ltd. (SII),…
Read More...

Everest Medicines a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products to address critical unmet needs in Asia Pacific markets,…
Read More...

Shenzhen Pregene Biopharma, a clinical-stage biopharmaceutical company engaged in discovering, developing, manufacturing and commercializes innovative medicines and CellPoint, a cell…
Read More...

BeiGene, Ltd. a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide,…
Read More...